Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.228
Buy
RSI(14)
59.215
Neutral
STOCH(KDJ)(9,3,3)
62.550
Neutral
ATR(14)
0.629
High Vlolatility
CCI(14)
100.192
Buy
Williams %R
33.852
Buy
TRIX(12,20)
0.256
Sell
StochRSI(14)
31.592
Sell
Day One Biopharmaceuticals Inc
DAWN9.600USD
-0.030-0.31%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
985.68MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Day One Biopharmaceuticals Inc
Currency: USD Updated: 2025-12-24Key Insights
Day One Biopharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 31/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 22.25.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Day One Biopharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
9
analysts
Buy
Current Rating
22.250
Target Price
+157.52%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Day One Biopharmaceuticals Inc Highlights
StrengthsRisks
Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. The Company’s commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor of mutant BRAF V600, wild-type BRAF, and wild-type CRAF kinases. Its pipeline product candidates include DAY301 and VRK1 program. The DAY301 candidate is a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody (mAb), conjugated with a topoisomerase I inhibitor through a stable and hydrophilic modified valine-alanine (VA) cleavable linker. Its VRK1 program is a novel target involved in the regulation of cell division and DNA damage repair.
Fairly Valued
The company’s latest PE is -6.28, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 86.52M shares, increasing 0.09% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 6.17M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.76.
Financial Health
Currency: USD Updated: 2025-12-24The current financial score of Day One Biopharmaceuticals Inc is 7.22, ranking 144/404 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 39.80M, representing a year-over-year decrease of 57.56%, while its net profit experienced a year-over-year decrease of 153.26%.
Score
Financials
6.60
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.90
Operational Efficiency
10.00
Growth Potential
5.42
Shareholder Returns
7.19
Day One Biopharmaceuticals Inc's Company Valuation
Currency: USD Updated: 2025-12-24The current valuation score of Day One Biopharmaceuticals Inc is 7.27, ranking 149/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -6.28, which is -32.83% below the recent high of -4.22 and -169.57% above the recent low of -16.93.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 31/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-24The current earnings forecast score of Day One Biopharmaceuticals Inc is 8.22, ranking 159/404 in the Biotechnology & Medical Research industry. The average price target for Day One Biopharmaceuticals Inc is 22.50, with a high of 29.00 and a low of 16.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
22.250
Target Price
+157.52%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Day One Biopharmaceuticals Inc
DAWN
9
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-24The current price momentum score of Day One Biopharmaceuticals Inc is 8.61, ranking 92/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 10.75 and the support level at 8.18, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
9.602
Sell
MA10
9.007
Buy
MA20
8.808
Buy
MA50
8.478
Buy
MA100
7.749
Buy
MA200
7.402
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-24The current institutional shareholding score of Day One Biopharmaceuticals Inc is 10.00, ranking 1/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 115.65%, representing a quarter-over-quarter decrease of 3.49%. The largest institutional shareholder is The Vanguard, holding a total of 6.17M shares, representing 6.01% of shares outstanding, with 2.68% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Access Industries, Inc.
Fidelity Management & Research Company LLC
Atlas Venture
BlackRock Institutional Trust Company, N.A.
Deerfield Management Company, L.P.
Franklin Advisers, Inc.
State Street Investment Management (US)
Vestal Point Capital, LP
1
2
Risk Assessment
Currency: USD Updated: 2025-12-24The current risk assessment score of Day One Biopharmaceuticals Inc is 5.08, ranking 66/404 in the Biotechnology & Medical Research industry. The company's beta value is -1.26. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
-1.26
VaR
--
240-Day Maximum Drawdown
+56.09%
240-Day Volatility
+67.42%
Return
Best Daily Return
60 days
+25.21%
120 days
+25.21%
5 years
--
Worst Daily Return
60 days
-14.41%
120 days
-15.70%
5 years
--
Sharpe Ratio
60 days
+1.88
120 days
+1.32
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+56.09%
3 years
+71.33%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.33
3 years
-0.24
5 years
--
Skewness
240 days
+0.58
3 years
+0.53
5 years
--
Volatility
Realised Volatility
240 days
+67.42%
5 years
--
Standardised True Range
240 days
+4.82%
5 years
--
Downside Risk-Adjusted Return
120 days
+208.08%
240 days
+208.08%
Maximum Daily Upside Volatility
60 days
+92.48%
Maximum Daily Downside Volatility
60 days
+48.68%
Liquidity
Average Turnover Rate
60 days
+1.54%
120 days
+1.41%
5 years
--
Turnover Deviation
20 days
+75.88%
60 days
+36.29%
120 days
+24.25%
Peer Comparison
Biotechnology & Medical Research
Day One Biopharmaceuticals Inc
DAWN
7.77 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Dynavax Technologies Corp
DVAX
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Day One Biopharmaceuticals Inc?
The TradingKey Stock Score provides a comprehensive assessment of Day One Biopharmaceuticals Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Day One Biopharmaceuticals Inc’s performance and outlook.
How do we generate the financial health score of Day One Biopharmaceuticals Inc?
To generate the financial health score of Day One Biopharmaceuticals Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Day One Biopharmaceuticals Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Day One Biopharmaceuticals Inc.
How do we generate the company valuation score of Day One Biopharmaceuticals Inc?
To generate the company valuation score of Day One Biopharmaceuticals Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Day One Biopharmaceuticals Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Day One Biopharmaceuticals Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Day One Biopharmaceuticals Inc.
How do we generate the earnings forecast score of Day One Biopharmaceuticals Inc?
To calculate the earnings forecast score of Day One Biopharmaceuticals Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Day One Biopharmaceuticals Inc’s future.
How do we generate the price momentum score of Day One Biopharmaceuticals Inc?
When generating the price momentum score for Day One Biopharmaceuticals Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Day One Biopharmaceuticals Inc’s prices. A higher score indicates a more stable short-term price trend for Day One Biopharmaceuticals Inc.
How do we generate the institutional confidence score of Day One Biopharmaceuticals Inc?
To generate the institutional confidence score of Day One Biopharmaceuticals Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Day One Biopharmaceuticals Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Day One Biopharmaceuticals Inc.
How do we generate the risk management score of Day One Biopharmaceuticals Inc?
To assess the risk management score of Day One Biopharmaceuticals Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Day One Biopharmaceuticals Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Day One Biopharmaceuticals Inc.
